中国循证医学杂志
中國循證醫學雜誌
중국순증의학잡지
CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE
2009年
7期
817-820
,共4页
姚南%姜雷%移康%杨克虎%闵光涛
姚南%薑雷%移康%楊剋虎%閔光濤
요남%강뢰%이강%양극호%민광도
循证治疗%直肠癌%化疗%放疗%手术
循證治療%直腸癌%化療%放療%手術
순증치료%직장암%화료%방료%수술
Evidence-based treatment%Lower rectal cancer%Chemotherapy%Radiotherapy%Surgery
目的 为一例确诊的低位直肠癌患者制定循证治疗方案.方法 针对低位直肠癌的治疗问题,提出问题,检索Cochrane Library(2009年第2期)、PubMed(1966~2009.5)、TRIP Database、SUM search、中国生物医学文献数据库(1989~2009.5)、中国科技期刊数据库(1989~2009.5)、中国期刊全文数据库(1994~2009.5),收集相关证据,对所获证据进行评价,并结合医生的经验及患者的愿望制定治疗方案.结果 共纳入24篇系统评价/Meta分析和1个临床指南.结果 显示:术前化放疗能降低直肠癌术后的局部复发率和病死率.与单纯术前放疗相比,术前化放疗联合可提高Ⅱ和Ⅲ期直肠癌疾病病理学反应和局部病变的控制,减低局部复发的风险;与术后放化疗相比,术前化放疗能降低局部复发的风险;与单纯手术相比,术后放疗并不能提高Ⅱ和Ⅲ期直肠癌患者的生存率,而术后化疗或术后放化疗却能提高患者术后的生存率;与传统的直肠癌外科根治术相比,全直肠系膜切除术(TME)能降低直肠癌术后局部复发率,从而提高患者的生存率和生活质量;经腹腔镜全直肠系膜切除术和开腹全直肠系膜切除术治疗直肠癌在病死率和复发率方面无差异.根据以上证据结合患者意愿,对该例患者术前采用5-Fu+LV方案化疗并联合放疗1月,后行开腹直肠癌根治术.术后半月患者恢复良好出院,出院后继续采用5-Fu+LV方案化疗6次.术后2年至今未见复发.结论 术前化放疗、术后化疗和术后放化疗能使直肠癌患者受益,TME是直肠癌的标准手术方式,但远期预后尚需要更长时间的随访观察.
目的 為一例確診的低位直腸癌患者製定循證治療方案.方法 針對低位直腸癌的治療問題,提齣問題,檢索Cochrane Library(2009年第2期)、PubMed(1966~2009.5)、TRIP Database、SUM search、中國生物醫學文獻數據庫(1989~2009.5)、中國科技期刊數據庫(1989~2009.5)、中國期刊全文數據庫(1994~2009.5),收集相關證據,對所穫證據進行評價,併結閤醫生的經驗及患者的願望製定治療方案.結果 共納入24篇繫統評價/Meta分析和1箇臨床指南.結果 顯示:術前化放療能降低直腸癌術後的跼部複髮率和病死率.與單純術前放療相比,術前化放療聯閤可提高Ⅱ和Ⅲ期直腸癌疾病病理學反應和跼部病變的控製,減低跼部複髮的風險;與術後放化療相比,術前化放療能降低跼部複髮的風險;與單純手術相比,術後放療併不能提高Ⅱ和Ⅲ期直腸癌患者的生存率,而術後化療或術後放化療卻能提高患者術後的生存率;與傳統的直腸癌外科根治術相比,全直腸繫膜切除術(TME)能降低直腸癌術後跼部複髮率,從而提高患者的生存率和生活質量;經腹腔鏡全直腸繫膜切除術和開腹全直腸繫膜切除術治療直腸癌在病死率和複髮率方麵無差異.根據以上證據結閤患者意願,對該例患者術前採用5-Fu+LV方案化療併聯閤放療1月,後行開腹直腸癌根治術.術後半月患者恢複良好齣院,齣院後繼續採用5-Fu+LV方案化療6次.術後2年至今未見複髮.結論 術前化放療、術後化療和術後放化療能使直腸癌患者受益,TME是直腸癌的標準手術方式,但遠期預後尚需要更長時間的隨訪觀察.
목적 위일례학진적저위직장암환자제정순증치료방안.방법 침대저위직장암적치료문제,제출문제,검색Cochrane Library(2009년제2기)、PubMed(1966~2009.5)、TRIP Database、SUM search、중국생물의학문헌수거고(1989~2009.5)、중국과기기간수거고(1989~2009.5)、중국기간전문수거고(1994~2009.5),수집상관증거,대소획증거진행평개,병결합의생적경험급환자적원망제정치료방안.결과 공납입24편계통평개/Meta분석화1개림상지남.결과 현시:술전화방료능강저직장암술후적국부복발솔화병사솔.여단순술전방료상비,술전화방료연합가제고Ⅱ화Ⅲ기직장암질병병이학반응화국부병변적공제,감저국부복발적풍험;여술후방화료상비,술전화방료능강저국부복발적풍험;여단순수술상비,술후방료병불능제고Ⅱ화Ⅲ기직장암환자적생존솔,이술후화료혹술후방화료각능제고환자술후적생존솔;여전통적직장암외과근치술상비,전직장계막절제술(TME)능강저직장암술후국부복발솔,종이제고환자적생존솔화생활질량;경복강경전직장계막절제술화개복전직장계막절제술치료직장암재병사솔화복발솔방면무차이.근거이상증거결합환자의원,대해례환자술전채용5-Fu+LV방안화료병연합방료1월,후행개복직장암근치술.술후반월환자회복량호출원,출원후계속채용5-Fu+LV방안화료6차.술후2년지금미견복발.결론 술전화방료、술후화료화술후방화료능사직장암환자수익,TME시직장암적표준수술방식,단원기예후상수요경장시간적수방관찰.
Objective To find individualized evidence-based treatments for a patient with lower rectal cancer. Methods Based on the clinical questions raised, evidence was collected and critically assessed. Patient preferences and physician clinical experience were also taken into consideration in the decision-making treatment. Results Twenty-four systematic reviews or meta analyses and 1 clinical guideline were induded. The evidence showed that preoperative chemoradio- therapy reduces risk of local recurrence and death from rectal cancer compared to preoperative radiotherapy alone. Preoperative combined chemoradiotherapy, enhanced pathological response and improved local control in the resemble stage II and III rectal cancer. Preoperative chemoradiotherapy reduced the risk of local recurrence as compared with postoperative chemoradiotherapy. Postoperative radiotherapy alone did not improve survival for the patients with resected stage Ⅱ and stage Ⅲ rectal cancer, whereas either chemotherapy alone or combined chemotherapy and radiotherapy improved survival in comparison with observation. As compared with conventional radical surgery, total mesorectum excision (TME) resulted in lower postoperative local recurrence rate and higher survival rate. No significant differences in terms of disease-free survival rate, local recurrence rate, mortality, and morbidity were found between laparoscopic and open total mesorectal excision. Conclusion The patients with lower rectal cancer might benefit from preoperative chemoradiotherapy, postoperative chemotherapy, and chemoradiotherapy. TME is the standard rectal cancer surgery. However, long-term prognostic benefits need to be confirmed by further follow-up.